Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?

Neuropeptides

Volumn 47, Issue 6, 2013, Pages 477-488

  Hoyer, Daniel ^a,b   Jacobson, Laura H ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Addiction; Feeding; Hypocretin; Hypothalamus; Insomnia; Narcolepsy cataplexy; Orexin; Orexin receptors; Reward; Sleep

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1 (6,8 DIFLUORO 2 METHYL 4 QUINOLINYL) 3 (4 DIMETHYLAMINOPHENYL)UREA; ACT 335827; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALMOREXANT; CHEMICALS AND DRUGS; FILOREXANT; JNJ 10397049; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; SB 649868; SUVOREXANT; UNCLASSIFIED DRUG;

ADDICTION; ALCOHOLISM; AMINO ACID SEQUENCE; AMYGDALOID NUCLEUS; ANTERIOR HYPOTHALAMUS; AROUSAL; CATAPLEXY; DORSAL RAPHE NUCLEUS; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; FEEDING BEHAVIOR; FOOD INTAKE; HIPPOCAMPUS; HUMAN; IMAGE SUBTRACTION; INSOMNIA; LATERAL HYPOTHALAMUS; NARCOLEPSY; NONHUMAN; NONREM SLEEP; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLACE PREFERENCE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REM SLEEP; REM SLEEP DEPRIVATION; REVIEW; SLEEP; SLEEP TIME; SLEEP WAKING CYCLE; STRIA TERMINALIS; SUPRACHIASMATIC NUCLEUS; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; VENTRAL TEGMENTUM;

CANIS FAMILIARIS; DORAS; MUS; RODENTIA;

ADDICTION; FEEDING; HYPOCRETIN; HYPOTHALAMUS; INSOMNIA; NARCOLEPSY/CATAPLEXY; OREXIN; OREXIN RECEPTORS; REWARD; SLEEP;

ACETAMIDES; ANIMALS; AZEPINES; BEHAVIOR, ADDICTIVE; BENZOFURANS; FEEDING BEHAVIOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOQUINOLINES; MICE; NEUROPEPTIDES; OREXIN RECEPTORS; PIPERIDINES; PYRIMIDINES; RATS; REWARD; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; THIAZOLES; TRIAZOLES;

EID: 84887991602     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2013.10.009     Document Type: Review

References (122)

1. Actelion, and GlaxoSmithKline. Actelion and GSK discontinue clinical development of almorexant. Available at: (accessed 28.01.11.). http://www.actelion.com/en/investors/media-releases/index.page?newsId=1483135.
2. Adamantidis A.R., Zhang F., Aravanis A.M., Deisseroth K., De Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007, 450:U9-U420.
3. Alvarez C.E., Sutcliffe J.G. Hypocretin is an early member of the incretin gene family. Neurosci. Lett. 2002, 324:169-172.
4. Annerbrink K., Westberg L., Olsson M., Andersch S., Sjödin I., Holm G., Allgulander C., Eriksson E. Panic disorder is associated with the Val308Iso polymorphism in the hypocretin receptor gene. Psychiatr. Genet. 2011, 21:85-89.
5. Baier P.C., Hallschmid M., Seeck-Hirschner M., Weinhold S.L., Burkert S., Diessner N., Goder R., Aldenhoff J.B., Hinze-Selch D. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med. 2011, 12:941-946.
6. Bergman J.M., Roecker A.J., Mercer S.P., Bednar R.A., Reiss D.R., Ransom R.W., Harrell C.M., Pettibone D.J., Lemaire W., Murphy K.L., Li C., Prueksaritanont T., Winrow C.J., Renger J.J., Koblan K.S., Hartman G.D., Coleman P.J. Proline bis-amides as potent dual orexin receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18:1425-1430.
7. Betschart C., Hintermann S., Behnke D., Cotesta S., Fendt M., Gee C., Jacobson L., Laue G., Ofner S., Chaudhari V., Badiger S., Pandit C., Wagner J., Hoyer D. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J. Med. Chem. 2013, 56:7590-7607.
8. Bettica P.U., Lichtenfeld U., Squassante L., Shabbir S., Zuechner D., Dreykluft P., Lehmann R., Danker-Hopfe H., Ratti E. The orexin antagonist SB-649868 promotes and maintains sleep in healthy volunteers and in patients with primary insomnia. Sleep 32. Abstract Suppl 2009, 0774:A252-A253.
9. Bettica P., Nucci G., Pyke C., Squassante L., Zamuner S., Ratti E., Gomeni R., Alexander R. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J. Psychopharmacol. 2012, 26:1058-1070.
10. Bettica P., Squassante L., Groeger J.A., Gennery B., Winsky-Sommerer R., Dijk D.J. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 2012, 37:1224-1233.
11. Bettica P., Squassante L., Zamuner S., Nucci G., Danker-Hopfe H., Ratti E. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 2012, 35:1097-1104.
12. Beuckmann C.T., Sinton C.M., Williams S.C., Richardson J.A., Hammer R.E., Sakurai T., Yanagisawa M. Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. J. Neurosci. 2004, 24:4469-4477.
13. Black S.W., Morairty S.R., Fisher S.P., Chen T.M., Warrier D.R., Kilduff T.S. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 2013, 36:325-336.
14. Boss C., Brisbare-Roch C., Jenck F., Aissaoui H., Koberstein R., Sifferlen T., Weller T. Orexin receptor antagonism: a new principle in neuroscience. Chimia 2008, 62:974-979.
15. Boss C., Brisbare-Roch C., Jenck F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J. Med. Chem. 2009, 52:891-903.
16. Boutrel B., Kenny P.J., Specio S.E., Martin-Fardon R., Markou A., Koob G.F., de Lecea L. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc. Natl. Acad. Sci. USA 2005, 102:19168-19173.
17. Boutrel B., Cannella N., de Lecea L. The role of hypocretin in driving arousal and goal-oriented behaviors. Brain Res. 2010, 1314:103-111.
18. Boutrel B., Steiner N., Halfon O. The hypocretins and the reward function: what have we learned so far?. Front. Behav. Neurosci. 2013, 7:1-10.
19. Brisbare-Roch C., Dingemanse J., Koberstein R., Hoever P., Aissaoui H., Flores S., Mueller C., Nayler O., van Gerven J., de Haas S.L., Hess P., Qiu C.B., Buchmann S., Scherz M., Weller T., Fischli W., Clozel M., Jenck F. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 2007, 13:150-155.
20. Callander, G.E., Olorunda, M., Monna, D., Schuepbach, E., Langenegger, D., Betschart, C., Hintermann, S., Behnke, D., Cotesta, S., Fendt, M., Laue, G., Ofner, S., Briard, E., Gee, C.E., Jacobson, L.H., Hoyer, D., in press. Kinetic properties of "dual" orexin receptor antagonists at OX1 and OX2 orexin receptors. Front. Neurosci. (Neuropharmacol.).
21. Carter M.E., Adamantidis A., Ohtsu H., Deisseroth K., de Lecea L. Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. J. Neurosci. 2009, 29:10939-10949.
22. Carter M.E., Brill J., Bonnavion P., Huguenard J.R., Huerta R., de Lecea L. Mechanism for hypocretin-mediated sleep-to-wake transitions. Proc. Natl. Acad. Sci. USA 2012, 109:E2635-E2644.
23. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y.M., Kisanuki Y., Fitch T.E., Nakazato M., Hammer R.E., Saper C.B., Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
24. Chou T.C., Lee C.E., Lu J., Elmquist J.K., Hara J., Willie J.T., Beuckmann C.T., Chemelli R.M., Sakurai T., Yanagisawa M., Saper C.B., Scammell T.E. Orexin (hypocretin) neurons contain dynorphin. J. Neurosci. 2001, 21(2):34-45. (art. no.-RC168).
25. Clark E.L., Baumann C.R., Cano G., Scammell T.E., Mochizuki T. Feeding-elicited cataplexy in orexin knockout mice. Neuroscience 2009, 161:970-977.
26. Cohrs S. Sleep disturbances in patients with schizophrenia impact and effect of antipsychotics. CNS Drugs 2008, 22:939-962.
27. Coleman P.J., Cox C.D., Roecker A.J. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia. Curr. Top. Med. Chem. 2011, 11:696-725.
28. Coleman P.J., Schreier J.D., Cox C.D., Breslin M.J., Whitman D.B., Bogusky M.J., McGaughey G.B., Bednar R.A., Lemaire W., Doran S.M., Fox S.V., Garson S.L., Gotter A.L., Harrell C.M., Reiss D.R., Cabalu T.D., Cui D.H., Prueksaritanont T., Stevens J., Tannenbaum P.L., Ball R.G., Stellabott J., Young S.D., Hartman G.D., Winrow C.J., Renger J.J. Discovery of (2R,5R)-5-{(5-Fluoropyridin-2-yl)oxymethyl}-2-methylpiperidin-1-yl-5-methyl-2-(pyrimidin-2-yl)phenylmethanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 2012, 7:415-424.
29. Coleman P.J., Schreier J.D., Roecker A.J., Mercer S.P., McGaughey G.B., Cox C.D., Hartman G.D., Harrell C.M., Reiss D.R., Doran S.M., Garson S.L., Anderson W.B., Tang C., Prueksaritanont T., Winrow C.J., Renger J.J. Discovery of 3,9-diazabicyclo 4.2.1 nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat. Bioorg. Med. Chem. Lett. 2010, 20:4201-4205.
30. Connor K., Budd K., Snavely D., Liu K., Hutzel-Mann J., Benca R., Krystal A., Roth T., Michelson D., Herring W.J. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #1). J. Sleep Res. 2012, 21:97.
31. Corporation, M.S.D., 2013. Suvorexant Advisory Committee Briefing Document. Available: ttp://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM352970.pdf.
32. Cox C.D., Breslin M.J., Whitman D.B., Schreier J.D., McGaughey G.B., Bogusky M.J., Roecker A.J., Mercer S.P., Bednar R.A., Lemaire W., Bruno J.G., Reiss D.R., Harrell C.M., Murphy K.L., Garson S.L., Doran S.M., Prueksaritanont T., Anderson W.B., Tang C.Y., Roller S., Cabalu T.D., Cui D.H., Hartman G.D., Young S.D., Koblan K.S., Winrow C.J., Renger J.J., Coleman P.J. Discovery of the dual orexin receptor antagonist (7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl 5-met hyl-2-(2H-1,2,3-triazol-2-yl)phenyl methanone (MK-4305) for the treatment of insomnia. J. Med. Chem. 2010, 53:5320-5332.
33. Date Y., Ueta Y., Yamashita H., Yamaguchi H., Matsukura S., Kangawa K., Sakurai T., Yanagisawa M., Nakazato M. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc. Natl. Acad. Sci. USA 1999, 96:748-753.
34. De Lecea L., Kilduff T.S., Peyron C., Gao X.B., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.L.F., Gautvik V.T., Bartlett F.S., Frankel W.N., van den Pol A.N., Bloom F.E., Gautvik K.M., Sutcliffe J.G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA 1998, 95:322-327.
35. Dugovic C., Shelton J.E., Aluisio L.E., Fraser I.C., Jiang X.H., Sutton S.W., Bonaventure P., Yun S.J., Li X.R., Lord B., Dvorak C.A., Carruthers N.I., Lovenberg T.W. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J. Pharmacol. Exp. Ther. 2009, 330:142-151.
36. Elias C.F., Saper C.B., Maratos-Flier E., Tritos N.A., Lee C., Kelly J., Tatro J.B., Hoffman G.E., Ollmann M.M., Barsh G.S., Sakurai T., Yanagisawa M., Elmquist J.K. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J. Comp. Neurol. 1998, 402:442-459.
37. Faedo S., Perdona E., Antolini M., di Fabio R., Pich E.M., Corsi M. Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists. Eur. J. Pharmacol. 2012, 692:1-9.
38. Farkas, R., 2013. Suvorexant Safety and Efficacy [Online]. www.fda.gov: U.S. Food and Drug Administration. Available: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM354215.pdf.
39. Fleming J.A.E. Rem-sleep abnormalities and psychiatry. J. Psychiatry Neurosci. 1994, 19:335-344.
40. Germain A., Nielsen T.A. Sleep pathophysiology in posttraumatic stress disorder and idiopathic nightmare sufferers. Biol. Psychiatry 2003, 54:1092-1098.
41. Gotter A.L., Webber A.L., Coleman P.J., Renger J.J., Winrow C.J. International union of basic and clinical pharmacology. LXXXVI. Orexin receptor function. Nomenclature and pharmacology. Pharmacol. Rev. 2012, 64:389-420.
42. Hakansson M.L., de Lecea L., Sutcliffe J.G., Yanagisawa M., Meister B. Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus. J. Neuroendocrinol. 1999, 11:653-663.
43. Hara J., Beuckmann C.T., Nambu T., Willie J.T., Chemelli R.M., Sinton C.M., Sugiyama F., Yagami K., Goto K., Yanagisawa M., Sakurai T. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001, 30:345-354.
44. Hara J., Yanagisawa M., Sakurai T. Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions. Neurosci. Lett. 2005, 380:239-242.
45. Hasler G., Manji H.K., Drevets M., Charney D. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004, 29:1765-1781.
46. Herring W.J., Ma J., Snyder E., Svetnik V., Hutzelmann J., Liu K., Lines C., Roth T., Michelson D. EEG power spectral profile of the orexin receptor antagonist suvorexant (MK-4305) in patients with primary insomnia and in healthy subjects. Sleep 2012, 35:A222.
47. Herring W.J., Ma J.S., Snyder E., Svetnik V., Hutzelmann J., Liu K., Lines C., Roth T., Michelson D. Power spectral profile of the orexin receptor antagonist suvorexant (MK-4305) in primary insomnia patients and healthy-subjects. Biol. Psychiatry 2012, 71:297S-298S.
48. Herring W.J., Snyder E., Budd K., Hutzelmann J., Snavely D., Liu K., Lines C., Roth T., Michelson D. Orexin receptor antagonism for treatment of insomnia A randomized clinical trial of suvorexant. Neurology 2012, 79:2265-2274.
49. Herring W.J., Snyder E., Paradis E., Hutzelmann J., Liu M.C., Snavely D., Walsh J., Krystal A., Roth T., Michelson D. Suvorexant, an orexin receptor antagonist, in preventing symptom return in patients with insomnia after 1year of treatment: a randomised, double-blind, placebo-controlled study. J. Sleep Res. 2012, 21:351.
50. Hoever P., de Haas S., Winkler J., Schoemaker R.C., Chiossi E., van Gerven J., Dingemanse J. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin. Pharmacol. Ther. 2010, 87:593-600.
51. Hoever P., de Haas S., Dorffner G., Chiossi E., van Gerven J., Dingemanse J. Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J. Psychopharmacol. 2012, 26:1071-1080.
52. Hoever P., Dorffner G., Benes H., Penzel T., Danker-Hopfe H., Barbanoj M.J., Pillar G., Saletu B., Polo O., Kunz D., Zeitlhofer J., Berg S., Partinen M., Bassetti C.L., Hogl B., Ebrahim I.O., Holsboer-Trachsler E., Bengtsson H., Peker Y., Hemmeter U.M., Chiossi E., Hajak G., Dingemanse J. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin. Pharmacol. Ther. 2012, 91:975-985.
53. Hoever P., Hay J., Rad M., Cavallaro M., van Gerven J.M., Dingemanse J. Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects. J. Clin. Psychopharmacol. 2013, 33:363-370.
54. Hoyer, D., Betschart, C., Hintermann, S., Behnke, D., Cotesta, S., Fendt, M., Laue, G., Ofner, S., Jacobson, L.H., Gee, C.E., in press. Distinct effects of orexin 2 receptor antagonism and dual orexin 1,2 receptor antagonism on sleep architecture in mice. Front. Neurosci. (Neuropharmacol.).
55. Hopkins C.R. ACS chemical neuroscience molecule spotlight on suvorexant. ACS Chem. Neurosci. 2012, 3:647-648.
56. Huang Z.L., Qu W.M., Li W.D., Mochizuki T., Eguchi N., Watanabe T., Urade Y., Hayaishi O. Arousal effect of orexin A depends on activation of hte histmic system. Proc. Natl. Acad. Sci. USA 2001, 98:9965-9970.
57. Ivgy-May N., Leibensperger H., Froman S., Hutzelmann J., Snavely D., Snyder E., Liu K., Walsh J., Roth T., Michelson D., Herring W.J. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #2). J. Sleep Res. 2012, 21:351-352.
58. Inutsuka A., Yamanaka A. The regulation of sleep and wakefulness by the hypothalamic neuropeptide orexin/hypocretin. Nagoya J. Med. Sci. 2013, 75:29-36.
59. Jenck F., Brisbare-Roch C., Scherz M., Flores S., Koberstein R., Nayler O., Dingemanse J., Clozel M. Reply to 'Promotion of sleep by targeting the orexin system in rats, dogs and humans' - Brisbare-Roch et al. reply. Nat. Med. 2007, 13:526.
60. Kenny P.J. Tobacco dependence, the insular cortex and the hypocretin connection. Pharmacol. Biochem. Behav. 2011, 97:700-707.
61. Kim A.K., Brown R.M., Lawrence A.J. The role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship. Front. Behav. Neurosci. 2012, 6:8.
62. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X.Y., Qiu X.H., de Jong P.J., Nishino S., Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
63. Liu M., Thankachan S., Kaur S., Begum S., Blanco-Centurion C., Sakurai T., Yanagisawa M., Neve R., Shiromani P.J. Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur. J. Neurosci. 2008, 28:1382-1393.
64. Lu X.Y., Bagnol D., Burke S., Akil H., Watson S.J. Differential distribution and regulation of OX1 and OX2 orexin/hypocretin receptor messenger RNA in the brain upon fasting. Horm. Behav. 2000, 37:335-344.
65. Malherbe P., Borroni E., Gobbi L., Knust H., Nettekoven M., Pinard E., Roche O., Rogers-Evans M., Wettstein J.G., Moreau J.L. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 receptor. Br. J. Pharmacol. 2009, 156:1326-1341.
66. Malherbe P., Borroni E., Pinard E., Wettstein J.G., Knoflach F. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX(1))/orexin 2 receptor (OX(2)) antagonist: comparison with selective OX(1) and OX(2) antagonists. Mol. Pharmacol. 2009, 76:618-631.
67. Malherbe P., Roche O., Marcuz A., Kratzeisen C., Wettstein J.G., Bissantz C. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino-N-pyridi n-3-ylmethyl-acetamide (EMPA). Mol. Pharmacol. 2010, 78:81-93.
68. Mang G.M., Durst T., Burki H., Imobersteg S., Abramowski D., Schuepbach E., Hoyer D., Fendt M., Gee C.E. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 2012, 35:1625-1635.
69. Mang G.M., Franken P. Sleep and EEG phenotyping in mice. Curr. Protocols Mouse Biol. 2012, 2:55-74.
70. Marcus J.N., Aschkenasi C.J., Lee C.E., Chemelli R.M., Saper C.B., Yanagisawa M., Elmquist J.K. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 2001, 435:6-25.
71. Mieda M., Williams S.C., Sinton C.M., Richardson J.A., Sakurai T., Yanagisawa M. Orexin neurons function in an efferent pathway of a food-entrainable circadian oscillator in eliciting food-anticipatory activity and wakefulness. J. Neurosci. 2004, 24:10493-10501.
72. Mieda M., Willie J.T., Hara J., Sinton C.M., Sakurai T., Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc. Natl. Acad. Sci. USA 2004, 101:4649-4654.
73. Mieda M., Hasegawa E., Kisanuki Y.Y., Sinton C.M., Yanagisawa M., Sakurai T. Differential roles of orexin receptor-1 and-2 in the regulation of non-REM and REM sleep. J. Neurosci. 2011, 31:6518-6526.
74. Mignot E. The perfect hypnotic?. Science 2013, 340:36-38.
75. Mignot E., Chen W., Black J. On the value of measuring CSF hypocretin-1 in diagnosing narcolepsy. Sleep 2003, 26:646-649.
76. Mignot E., Lin L., Rogers W., Honda Y., Qiu X.H., Lin X.Y., Okun M., Hohjoh H., Miki T., Hsu S.H., Leffell M.S., Grumet F.C., Fernandez-Vina M., Honda M., Risch N. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am. J. Hum. Genet. 2001, 68:686-699.
77. Mignot E., Taheri S., Nishino S. Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nat. Neurosci. 2002, 5:1071-1075.
78. Mignot E.J., Lammers G., Ripley B., Okun M., Nevsimalova S., Overeem R., Black J., Harsh J., Bassetti C., Nishino S. Clinical overlaps of the narcolepsy and hypocretin/orexin deficiency syndromes. Sleep 2002, 25:A76-A77.
79. Mochizuki T., Crocker A., McCormack S., Yanagisawa M., Sakurai T., Scammell T.E. Behavioral state instability in orexin knock-out mice. J. Neurosci. 2004, 24:6291-6300.
80. Morairty S.R., Revel F.G., Malherbe P., Moreau J.L., Valladao D., Wettstein J.G., Kilduff T.S., Borroni E. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS ONE 2012, 7:e39131.
81. Morawska M., Buchi M., Fendt M. Narcoleptic episodes in orexin-deficient mice are increased by both attractive and aversive odors. Behav. Brain Res. 2011, 222:397-400.
82. Nambu T., Sakurai T., Mizukami K., Hosoya Y., Yanagisawa M., Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res. 1999, 827:243-260.
83. Neubauer D.N. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia. Curr. Opin. Investig. Drugs 2010, 11:101-110.
84. Nishino S., Okura M., Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med. Rev. 2000, 4:57-99.
85. Nishino S., Ripley B., Overeem S., Lammers G.J., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
86. Nishino S., Ripley B., Overeem S., Nevsimalova S., Lammers G.J., Vankova J., Okun M., Rogers W., Brooks S., Mignot E. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. 2001, 50:381-388.
87. Nishino S., Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol. 1997, 52:27-78.
88. Owen R.T., Castaner R., Bolos J., Estivill C. ALMOREXANT dual orexin OX1/OX2 antagonist treatment of sleep disorders. Drugs Future 2009, 34:5-10.
89. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., Nevsimalova S., Aldrich M., Reynolds D., Albin R., Li R., Hungs M., Pedrazzoli M., Padigaru M., Kucherlapati M., Fan J., Maki R., Lammers G.J., Bouras C., Kucherlapati R., Nishino S., Mignot E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 2000, 6:991-997.
90. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 1998, 18:9996-10015.
91. Peyron C., Valentin F., Bayard S., Hanriot L., Bedetti C., Rousset B., Luppi P.H., Dauvilliers Y. Melanin concentrating hormone in central hypersomnia. Sleep Med. 2011, 12:768-772.
92. Radl S. SUVOREXANT dual orexin OX1/OX2 receptor antagonist treatment of sleep disorders. Drugs Future 2013, 38:27-36.
93. Rainero I., Gallone S., Rubino E., Ponzo P., Valfre W., Binello E., Fenoglio P., Gentile S., Anoaica M., Gasparini M., Pinessi L. Haplotype analysis confirms the association between the HCRTR2 gene and cluster headache. Headache 2008, 48:1108-1114.
94. Reti I.M., Reddy R., Worley P.F., Baraban J.M. Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons. J. Neurochem. 2002, 82:1561-1565.
95. Risold P.Y., Griffond B., Kilduff T.S., Sutcliffe J.G., Fellmann D. Preprohypocretin (orexin) and prolactin-like immunoreactivity are coexpressed by neurone of the rat lateral hypothalamic area. Neurosci. Lett. 1999, 259:153-156.
96. Rosin D.L., Weston M.C., Sevigny C.P., Stornetta R.L., Guyenet P.G. Hypothalamic orexin (Hypocretin) neurons express vesicular glutamate transporters VGLUT1 or VGLUT2. J. Comp. Neurol. 2003, 465:593-603.
97. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat. Rev. Neurosci. 2007, 8:171-181.
98. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., Williams S.C., Richardson J.A., Kozlowski G.P., Wilson S., Arch J.R.S., Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., McNulty D.E., Liu W.S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
99. Sakurai T., Nagata R., Yamanaka A., Kawamura H., Tsujino N., Muraki Y., Kageyama H., Kunita S., Takahashi S., Goto K., Koyama Y., Shioda S., Yanagisawa M. Input of orexin/hypocretin by a genetically encoded neurons revealed tracer in mice. Neuron 2005, 46:297-308.
100. Saper C.B., Cano G., Scammell T.E. Homeostatic, circadian, and emotional regulation of sleep. J. Comp. Neurol. 2005, 493:92-98.
101. Saper C.B., Chou T.C., Scammell T.E. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001, 24:726-731.
102. Sasaki K., Suzuki M., Mieda M., Tsujino N., Roth B., Sakurai T. Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice. Plos ONE 2011, 6:e20360.
103. Shibahara M., Sakurai T., Nambu T., Takenouchi T., Iwaasa H., Egashira S.I., Ihara M., Goto K. Structure, tissue distribution, and pharmacological characterization of Xenopus orexins. Peptides 1999, 20:1169-1176.
104. Shoblock J.R., Welty N., Aluisio L., Fraser I., Motley S.T., Morton K., Palmer J., Bonaventure P., Carruthers N.I., Lovenberg T.W., Boggs J., Galici R. Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology 2011, 215:191-203.
105. Smith M.I., Piper D.C., Duxon M.S., Upton N. Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci. Lett. 2003, 341:256-258.
106. Steiner M.A., Gatfield J., Brisbare-Roch C., Dietrich H., Treiber A., Jenck F., Boss C. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type1 selective antagonist. ChemMedChem 2013, 8:898-903.
107. Sun H., Kennedy W.P., Wilbraham D., Lewis N., Calder N., Li X., Ma J., Yee K.L., Ermlich S., Mangin E., Lines C., Rosen L., Chodakewitz J., Murphy G.M. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 2013, 36:259-267.
108. Tafti M. Reply to 'promotion of sleep by targeting the orexin system in rats, dogs and humans'. Nat. Med. 2007, 13:525-526.
109. Tafti M., Maret S., Dauvilliers Y. Genes for normal sleep and sleep disorders. Ann. Med. 2005, 37:580-589.
110. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., Cornford M., Siegel J.M. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
111. Thompson M.D., Comings D.E., Abu-Ghazalah R., Jereseh Y., Lin L., Wade J., Sakurai T., Tokita S., Yoshida T., Tanaka H., Yanagisawa M., Burnham W.M., Moldofsky H. Variants of the orexin2/hcrt2 receptor gene identified in patients with excessive daytime sleepiness and patients with Tourette's syndrome comorbidity. Am. J. Med. Genet. Part B, Neuropsychiatric Genet.: Official Publ. Int. Soc. Psychiatric Genet. 2004, 129B:69-75.
112. Torrealba F., Yanagisawa M., Saper C.B. Colocalization of orexin and glutamate immunoreactivity in axon terminals in the tuberomammillary nucleus in rats. Neuroscience 2003, 119:1033-1044.
113. Trivedi P., Yu H., MacNeil D.J., Van der Ploeg L.H.T., Guan X.M. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 1998, 438:71-75.
114. Tsujino N., Sakurai T. Role of orexin in modulating arousal, feeding, and motivation. Front. Behav. Neurosci. 2013, 7:1-14.
115. Tsunematsu T., Kilduff T.S., Boyden E.S., Takahashi S., Tominaga M., Yamanaka A. Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. J. Neurosci. 2011, 31:10529-10539.
116. Uslaner, J.M., Tye, S.J., Eddins, D.M., Wang, X.H., Fox, S.V., Savitz, A.T., Binns, J., Cannon, C.E., Garson, S.L., Yao, L.H., Hodgson, R., Stevens, J., Bowlby, M.R., Tannenbaum, P.L., Brunner, J., McDonald, T.P., Gotter, A.L., Kuduk, S.D., Coleman, P.J., Winrow, C.J., Renger, J.J., 2013. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci. Transl. Med. 5, 179ra44.
117. Willie J.T., Chemelli R.M., Sinton C.M., Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu. Rev. Neurosci. 2001, 24:429-458.
118. Willie J.T., Chemelli R.M., Sinston C.M., Tokita H., Williams S.C., Kisanuki Y.Y., Marcus J.N., Lee C., Elmquist J.K., Kohlmeier K.A., Leonard C.S., Richardson J.A., Hammer R.E., Yanagisawa M. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003, 38:715-730.
119. Winrow C.J., Gotter A.L., Cox C.D., Doran S.M., Tannenbaum P.L., Breslin M.J., Garson S.L., Fox S.V., Harrell C.M., Stevens J., Reiss D.R., Cui D.H., Coleman P.J., Renger J.J. Promotion of sleep by suvorexant - a novel dual orexin receptor antagonist. J. Neurogenet. 2011, 25:52-61.
120. Winrow C.J., Gotter A.L., Cox C.D., Tannenbaum P.L., Garson S.L., Doran S.M., Breslin M.J., Schreier J.D., Fox S.V., Harrell C.M., Stevens J., Reiss D.R., Cui D.H., Coleman P.J., Renger J.J. Pharmacological characterization of MK-6096-A dual orexin receptor antagonist for insomnia. Neuropharmacology 2012, 62:978-987.
121. Yamanaka A., Tsujino N., Funahashi H., Honda K., Guan J.L., Wang Q.P., Tominaga M., Goto K., Shioda S., Sakurai T. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem. Biophys. Res. Commun. 2002, 290:1237-1245.
122. Yamanaka A., Beuckmann C.T., Willie J.T., Hara J., Tsujino N., Mieda M., Tominaga M., Yagami K., Sugiyama F., Goto K., Yanagisawa M., Sakurai T. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003, 38:701-713.